Prophylaxis of chronic kidney disease after liver transplantation - experience from west China

Table 1 Clinical features between chronic kidney disease and non-chronic kidney diseas recipients n (%)

Clinical features	CKD group (n = 99)	Non-CKD group (n = 473)	P value
Age (median years)	49	42	0.001
Sex (male/female)	70/29	408/65	0.001
Donor type (DDLT/LDLT)	82/17	350/123	NS
Indications for LT
Cirrhosis	38 (38.4)	160 (33.8)	NS
Chronic active hepatitis	13 (13.1)	39 (8.2)	NS
Tumors	34 (34.3)	234 (49.5)	0.006
Others	14 (14.1)	40 (8.5)	NS
HBV infection	80 (80.8)	401 (85.0)	NS
Complications pre-LT
DM	10 (10.1)	26 (5.5)	NS
Renal dysfunction	22 (22.2)	32 (6.8)	0.001
HRS	11 (11.1)	16 (3.4)	0.003
Hemodialysis	9 (9.1)	10 (2.1)	0.002
Hypertension	5 (5.1)	8 (1.7)	NS
MELD scores	14	11	0.001
CNI type (TAC/CSA)	64/35	365/108	0.009
MMF adoption	49 (49.5)	310 (65.5)	0.003
Complications post-LT
DM	27 (27.3)	85 (18.0)	0.034
Hypertension	19 (19.2)	35 (7.4)	0.001
Hypercholesterolemia	19 (19.2)	57 (12.1)	NS
Hypertriglyceridemia	26 (26.3)	81 (17.1)	0.034
AKI	32 (32.3)	53 (11.2)	0.001
AR	18 (18.2)	56 (11.8)	NS
CR	4 (4.0)	11 (2.3)	NS
Graft failure	6 (6.1)	11 (2.3)	NS
Re-transplantation	5 (5.1)	8 (1.7)	NS

CKD: Chronic kidney disease; Age: Age at transplantation; DDLT: Deceased donor liver transplantation, LDLT: Living donor liver transplantation; NS: No significance; LT: Liver transplantation; HBV: Hepatitis B Virus; DM: Diabetes mellitus; HRS: Hepatorenal syndrome; MELD: Mayo end-stage liver disease; CNI: Calcineurin Inhibitor; TAC: Tacrolimus; CSA: Cyclosporine A; MMF: Mycophenolate mofetil; AKI: Acute kidney injury; AR: Acute rejection; CR: Chronic rejection.